• Publications
  • Influence
Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire.
The Mood Disorder Questionnaire is a useful screening instrument for bipolar spectrum disorder in a psychiatric outpatient population and has good sensitivity and very good specificity. Expand
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
Quetiapine monotherapy is efficacious and well tolerated for the treatment of bipolar depression and demonstrated statistically significant improvement in Montgomery-Asberg Depression Rating Scale total scores compared with placebo from week 1 onward. Expand
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
Screening for bipolar disorder in the community.
The positive MDQ screen rate of 3.7% suggests that nearly 4% of American adults may suffer from bipolar I and II disorders, and young adults and individuals with lower income are at greater risk for this largely underdiagnosed disorder. Expand
Validity of the mood disorder questionnaire: a general population study.
The Mood Disorder Questionnaire is a useful screening instrument for bipolar I and II disorders in the community and its operating characteristics in the general population differ substantially from its characteristics in outpatient psychiatric settings. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
Divalproex was as effective in rapid-cycling manic patients as in other patients and appears to be independent of prior responsiveness to lithium, while lithium was significantly more effective than placebo in reducing the symptoms of acute mania. Expand
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar
The Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder in 2005, with a 2007 update. This second update, in conjunction with theExpand
Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study)
It is demonstrated that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study. Expand
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. Expand